The type of SARS‐CoV‐2 vaccine influences serological response in kidney transplant recipients. Issue 4 (18th January 2022)

• Record Type: Journal Article
• Authors: Correia, Ana Luísa; Leal, Rita; Pimenta, Ana Carolina; Fernandes, Mariana; Guedes Marques, Maria; Rodrigues, Luís; Santos, Lídia; Romãozinho, Catarina; Sá, Helena; Pratas, Jorge; Araújo, Lucília; Figueiredo, Arnaldo; Alves, Rui
• Is Part Of: Clinical transplantation. Volume 36:Issue 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-18
• Subjects: COVID‐19 -- immune response -- kidney transplantation -- SARS‐CoV‐2 infection -- vaccines; Transplantation of organs, tissues, etc -- Periodicals; 617.95
• DOI: 10.1111/ctr.14585
• Languages: English
• ISSNs: 0902-0063

Abstract

Abstract: Vaccination is a promising strategy to control the ongoing pandemic; however, solid organ recipients tend to develop a weaker immune response to vaccination. Anti‐spike SARS‐CoV‐2 antibodies titers were measured 2–4 weeks post‐vaccination completion in 131 KT patients without previous infection. Demographic, clinical, and laboratorial parameters were analyzed to identify which factors contributed to seroconversion. Factors that influenced seroconversion, that occurred in 76 patients (58%), were longer time post‐transplant, immunosuppression without an antiproliferative drug and vaccination with mRNA vaccines. Patients who received mRNA vaccines had significantly higher rates of seroconversion compared with adenovirus vector vaccines (67% vs 33%, P < .001) and higher anti‐spike IgG titers. These findings reinforce the need to discuss the vaccination strategy in this population, including a third dose with a mRNA vaccine.